Beckley Psytech
Born out of the Beckley Foundation and underpinned by two decades of scientific research, Beckley Psytech are combining world-leading psychedelic science, clinical drug development expertise and a pioneering approach to the use of digital tools in order to optimize patient outcomes, revolutionise treatment and ease the burden these conditions have on patients and society.
Latest Beckley Psytech Content
Article
The Pulse: Psychedelic News From Technology Networks Issue 4
Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.
Article
The Pulse: Psychedelic News From Technology Networks Issue 2
Hello and welcome to the Pulse, the monthly psychedelics industry roundup from Technology Networks and Analytical Cannabis. Here, we’ll highlight some of the most significant psychedelic industry news from the past month, including important announcements, pre-clinical work and the latest from groundbreaking psychedelic clinical trials.
Industry Insight
What’s the Best Way To Take 5-MeO-DMT in a Clinical Trial?
Beckley Psytech recently announced that they have dosed the first healthy volunteers in their Phase I trial of an intranasally delivered formulation of 5-MeO-DMT, named BPL-003. To find out more about their trial approach and wider research into 5-MeO-DMT, we spoke to Beckley’s chief scientific offer, Dr. Steve Wooding.
Video
TSE Explores Psychedelics – The Next Generation of Psychedelic Drugs
In this episode, Lucy Lawrence interviews Cosmo Feilding-Mellen CEO of Beckley Psytech about the next generation of psychedelic drugs.
Advertisement
